About The Clatterbridge Cancer Centre

The Clatterbridge Cancer Centre is one of the largest networked cancer centres in the UK.

Combining its world-class clinical services, research and academic excellence, the Centre provides the highest quality, specialist nonsurgical oncology treatment and care for more than 2.3 million residents in Cheshire, Merseyside, North Wales and the Isle of Man as well as national and international cancer patients.

It cares for more than 30,000 patients per year, with in excess of 220,000 patient contacts for treatment/appointments. The Centre registers almost 8,000 new patients each year.

More than 1000 staff are employed at the Centre, with volunteers providing additional support and services. The Trust spends approximately £88m per year on all aspects of cancer treatment, diagnosis and care.

The Trust’s Wirral-based treatment centre is supported by a £17m radiotherapy satellite facility in Aintree, Liverpool and specialist chemotherapy clinics in seven of Merseyside’s district hospitals. Together, this enables the Centre to provide a comprehensive range of radiotherapy (including low energy proton beam treatments) and chemotherapy treatments in outpatient and inpatient settings across Cheshire and Merseyside.

The Centre annually delivers over 44,000 outpatient chemotherapy treatments and over 1,100 inpatient treatments.

The Trust also provides outpatient consultations, diagnostic imaging services and support services and delivers the Acute Oncology medical service across the network.

The Trust is part of the Merseyside and Cheshire Cancer Network and is a full participant in all Clinical Network Groups and Multi-disciplinary Teams.

The Clatterbridge Cancer Centre’s Wirral-based treatment centre houses the Delamere Day-Case Unit which offers specialist chemotherapy in comfortable treatment bays. It also operates specialist, weekly chemotherapy clinics in eight of the region’s district hospitals, to ensure that patients are within just a few miles of world-class chemotherapy treatment. The Centre annually delivers over 44,000 outpatient chemotherapy treatments and over 1,100 inpatient treatments.

To complement this, it operates a community chemotherapy service which offers specialist treatment away from a hospital setting and enables some patients to have access to the best possible care in the most convenient place.

The Clatterbridge Cancer Centre boasts one of the largest medical radiation services in the UK, to deliver standard and specialist radiotherapy offering faster, more effective diagnosis and treatment to help fight a wide range of cancers.

It employs more than 120 therapy radiographers who work with clinical oncologists, specialist on-site physicians, clinical scientists and medical technologists to complete a team of experts. Its specialists use world-class, computer-based systems to plan intricate, individual treatments for more than 450 patients each month.

The department features some of the most modern radiotherapy and imaging facilities anywhere in Europe and the Centre’s comprehensive suite of facilities includes ten linear accelerators, x ray treatment machines, two simulators, two scanners and planning and diagnosis systems as well as pioneering stereotactic radiotherapy facilities.

The Trust has also developed a satellite radiotherapy centre at Aintree, aimed at providing care as close to patients’ homes as possible.

The Centre is the first and only cancer centre in the UK with a world-class, proton therapy facility to treat eye tumours. It was the first centre in the UK to introduce Novalis Tx treatment system when it launched the revolutionary treatment in 2011. It also pioneered the use of Papillon radiotherapy and was the first British centre to introduce the treatment in 1992. The Clatterbridge Cancer Centre now operates one of the largest radiotherapy centres in the North West, delivering nearly 100,000 treatments each year.

The Trust was one of the first cancer centres to support the development of an acute oncology service across all our local district general hospitals with Accident and Emergency departments.

It is leading on the development of comprehensive survivorship programmes, having participated in the Department of Health pilot programme.

It runs a comprehensive oncology education programme through its Clinical Education Department and benefits from increasing opportunities in research with academic departments and close links with local universities.

Research and development, including participation in national and international clinical trials, is an important feature of the cancer centre.

The Trust has an established track-record of providing high-quality cancer care by expert staff, state-of-the-art equipment, cytotoxic therapy and a well established research programme. High-quality care has been demonstrated by its excellent performance in respect of mandated targets and indicators, the achievement of national awards and accreditations and continuous patient feedback. National patient survey results routinely place The Clatterbridge Cancer Centre within the top 20% of Trusts in England.

The Centre is now poised at one of the most significant points in its history. It is committed to transforming cancer care through the development of a new centre located in Liverpool. The Transforming Cancer Care project is a once-in-a-generation opportunity to develop cancer services that will ensure the people of Cheshire, Merseyside and beyond continue to benefit from care of the highest quality for decades to come.

The new centre, due to open in 2020, will be located on the Liverpool health campus alongside the Royal Liverpool University Hospital, the University of Liverpool and other key research partners. The Trust will continue to operate outpatient services and proton therapy at its Wirral site, as well as its outpatient radiotherapy services at Aintree and the outpatient chemotherapy clinics across Cheshire and Merseyside. Inpatient services and complex chemotherapy and radiotherapy will move to the new centre but the majority of Wirral patients will continue to receive their care at the current site.

The project has three key benefits:

  • Seriously-ill patients with other health conditions (e.g. heart, lung and kidney) as well as cancer would have on-site access to intensive care and support from other key medical and surgical specialties for the first time. This is becoming increasingly important as the population ages and has more complex health needs.
  • It would mean the main Clatterbridge site with inpatient chemotherapy and radiotherapy expertise was much more centrally located for the population it serves, reducing travel times for the majority of patients. Around 70% of its patients live north of the Mersey, whereas the Wirral site is in the south of its catchment area.
  • Bringing the Centre onto the same site as the university, Royal Liverpool and other key research partners would significantly increase opportunities for groundbreaking research and clinical trials, enabling patients in Cheshire and Merseyside to benefit from greater access to the latest expertise and treatments.

Transforming Cancer Care will enable the Centre to play a major part in overcoming the specific cancer challenges that face Cheshire and Merseyside e.g.:

  • More than 5,500 people die each year from cancer in Cheshire and Merseyside.
  • The number of new cancer cases and the number of cancer deaths in this region are significantly higher than the national average (new cases of lung cancer in Cheshire and Merseyside are 15% and 23% higher than the national average for men and women respectively).
  • The incidence of cancer is expected to rise significantly in the next few years.
  • The Centre has a strong track record of leading transformational change and delivering high-quality care over many years. It aims to continue on this journey through the delivery of this strategic plan.

All this is achieved through expert, dedicated staff, supported by a values-driven organisational culture.